Published in Vaccine Weekly, February 15th, 2006
The purchase price of approximately GBP 20 million (approx. EUR 29.3 million) will be paid via approximately GBP 14 million (approx. EUR 20.5 million) cash and through the issuance of 208,560 new MorphoSys shares from a capital increase against contribution in kind. Serotec provides MorphoSys with a strong distribution network including subsidiaries and sales...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly